Last reviewed 2026-04-20 · How we verify

Racemic Sibutramine (SIBUTRAMINE)

Racemic Sibutramine, also known as SIBUTRAMINE, is a small molecule Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic. It was originally developed and is currently owned by a pharmaceutical company. Sibutramine targets the sodium-dependent serotonin transporter, which is involved in regulating mood and appetite. It was FDA approved in 1997 for the treatment of obesity, but is now off-patent and no longer commercially available. As a result, there are no generic manufacturers of the drug.

At a glance

Approved indications

• Obesity

Common side effects

No common side effects on file.

Drug interactions

• citalopram
• desvenlafaxine
• escitalopram
• fluoxetine
• fluvoxamine
• naratriptan
• nefazodone
• paroxetine
• sertraline
• sumatriptan
• tapentadol
• tramadol

Key clinical trials

• A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (PHASE3)
• Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity
• Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity (PHASE4)
• Treatment of Binge Eating in Obese Patients in Primary Care (PHASE4)
• Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care (NA)
• Studying the Effects of Sibutramine on Eating Behavior (PHASE4)
• A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects (PHASE1)
• Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.